HCPCS Codes for Pneumococcal/flu vaccine


  • G0008

    Administration of influenza virus vaccine
  • G0009

    Administration of pneumococcal vaccine
  • M0201

    Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home
  • M0239

    Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
  • M0240

    Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
  • M0241

    Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
  • M0243

    Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring
  • M0244

    Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
  • M0245

    Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
  • M0246

    Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency
  • M0247

    Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
  • M0248

    Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
  • M0249

    Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
  • M0250

    Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
  • Q0239

    Injection, bamlanivimab-xxxx, 700 mg
  • Q0240

    Injection, casirivimab and imdevimab, 600 mg
  • Q0243

    Injection, casirivimab and imdevimab, 2400 mg
  • Q0244

    Injection, casirivimab and imdevimab, 1200 mg
  • Q0245

    Injection, bamlanivimab and etesevimab, 2100 mg
  • Q0247

    Injection, sotrovimab, 500 mg
  • Q0249

    Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
  • Q2034

    Influenza virus vaccine, split virus, for intramuscular use (agriflu)
  • Q2035

    Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
  • Q2036

    Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
  • Q2037

    Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
  • Q2038

    Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
  • Q2039

    Influenza virus vaccine, not otherwise specified